Axillary ultrasound after neoadjuvant therapy reduces the false-negative rate of sentinel lymph node biopsy in patients with cytologically node-positive breast cancer

[11] Reintgen DS(2017)ACR appropriateness criteria((R)) monitoring response to neoadjuvant systemic therapy for breast cancer J Am Coll Radiol 14 S462-57

[12] Blumencranz PW(2019)Predicting axillary response to neoadjuvant chemotherapy: breast MRI and US in patients with node-positive breast cancer Radiology 293 49-1469

[13] Leitch AM(2020)Prediction of axillary response by monitoring with ultrasound and MRI during and after neoadjuvant chemotherapy in breast cancer patients Eur Radiol 30 1460-1299

[14] Saha S(2021)Imaging updates to breast cancer lymph node management Radiographics 41 1283-207

[15] Hunt KK(2017)Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy—results from the multi-center SENTINA trial Breast 31 202-108

[16] Giuliano AE(2017)The use of ultrasound in the clinical re-staging of the axilla after neoadjuvant chemotherapy (NACT) Breast 35 104-700

[17] Mamounas EP(2021)Diagnostic performance of noninvasive imaging for assessment of axillary response after neoadjuvant systemic therapy in clinically node-positive breast cancer: a systematic review and meta-analysis Ann Surg 273 694-3393

[18] Brown A(2015)Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: results from the American college of surgeons oncology group Z1071 trial (alliance) J Clin Oncol 33 3386-4345

[19] Anderson S(2019)Axillary lymph node ultrasound following neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: results from the SN FNAC study Ann Surg Oncol 26 4337-269

[20] Smith R(2021)Feasibility and reliability of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients with positive axillary nodes at initial diagnosis: an up-to-date meta-analysis of 3578 patients Breast 59 256-8642

[11] Reintgen DS(2017)ACR appropriateness criteria((R)) monitoring response to neoadjuvant systemic therapy for breast cancer J Am Coll Radiol 14 S462-57

[12] Blumencranz PW(2019)Predicting axillary response to neoadjuvant chemotherapy: breast MRI and US in patients with node-positive breast cancer Radiology 293 49-1469

[13] Leitch AM(2020)Prediction of axillary response by monitoring with ultrasound and MRI during and after neoadjuvant chemotherapy in breast cancer patients Eur Radiol 30 1460-1299

[14] Saha S(2021)Imaging updates to breast cancer lymph node management Radiographics 41 1283-207

[15] Hunt KK(2017)Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy—results from the multi-center SENTINA trial Breast 31 202-108

[16] Giuliano AE(2017)The use of ultrasound in the clinical re-staging of the axilla after neoadjuvant chemotherapy (NACT) Breast 35 104-700

[17] Mamounas EP(2021)Diagnostic performance of noninvasive imaging for assessment of axillary response after neoadjuvant systemic therapy in clinically node-positive breast cancer: a systematic review and meta-analysis Ann Surg 273 694-3393

[18] Brown A(2015)Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: results from the American college of surgeons oncology group Z1071 trial (alliance) J Clin Oncol 33 3386-4345

[19] Anderson S(2019)Axillary lymph node ultrasound following neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: results from the SN FNAC study Ann Surg Oncol 26 4337-269

[20] Smith R(2021)Feasibility and reliability of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients with positive axillary nodes at initial diagnosis: an up-to-date meta-analysis of 3578 patients Breast 59 256-8642